{"prompt": "['10', 'I: Protocol Synopsis', '1.1: Title.', 'Validation of Bulbicam for use on patient suffering from Diabetic retinopathy ((DR) and Age-', 'related macular degeneration (AMD)', '1.2: Protocol number', 'Protocol number: V1_OTH/DR; AMD - I/2022', '1.3: Aim', 'To investigate repeatability and stability of the six OTH-related Bulbicam tests in', 'patients suffering from a) Diabetic retinopathy (DR), b) Age related macular', 'degeneration (AMD) and matched healthy controls (HC).', 'To compare Bulbicam and the Standard Method on measurements of Visual Field and', 'Pupil', 'To contribute to the establishment of normal range for DR and AMD patients with', 'different degree in the disease development related to the Bulbicam tests.', 'To contribute to the establishment of normal range for a normal population without', 'eye-disease related to the Bulbicam tests.', '1.4: Study population', 'The study consists of the following three study populations: 1) Patients suffering from DR of', 'both genders above 18 years of age with different disease degree; 2) Patients suffering from', 'AMD of both genders above 18 years of age with different disease degree; 3) Gender- and', 'age-matched HC without any eye diseases.', '1.5: Trial equipment', 'Bulbicam will be used in the study and the following six tests will be performed at each', 'investigation: \"Neurofield 64\", \"Ptosis\", \"Dynamic Acuity\", \"Dynamic Contrast \"Dark', 'Adoption\" and Pupil. The Standard Method will be used initially for measurements of', '\"Neurofield64\", \"Visual Field\" and \"pupil\".', '1.6: Design', 'The study will be performed as a controlled, open, and non-randomized, stratified', 'observational multicenter study. The stratification factors are the pathology of DR and AMD', 'and the degree of disease. Within each of the four strata, healthy matched controls related to', 'gender- and age (1:1) will be included. The degree of DR is defined as follows:', '1) Mild retinopathy: Mild nonproliferative diabetic retinopathy', '2) Moderate retinopathy: Moderate nonproliferative diabetic retinopathy', 'The degree of AMD is defined as follows:', '1) Early AMD', '2) Intermediate', 'BulbiCam; Validity study:', 'V1_OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']['11', 'For each included patient, a gender- and age-matched HC will be included. All included', 'participants will perform Bulbicam eye-investigation twice at three flowing days with a rest', 'period of at least one hour. Each investigation includes same six Bulbicam tests. The Standard', 'method will only be performed once as the first investigation at day 1 for measurements of', '\"Visual Field\" and Pupil\"', '1.7: Variables', '1.7.1 Main Variables', 'The main variables will be the variables recorded at the six Bulbicam tests described in the', 'table below:', 'TEST', 'VARIABLE', 'UNIT', 'FORMAT', 'Seen/unseen (0)', '0= unseen target', 'xml.', 'Saccadic Reaction Time', 'Ms - 4 digits, 0 decimals', 'xml.', 'Visual Field', 'Angular deviation', 'Degree - 3 digits, 0 decimals', 'xml.', 'X-coordinate', 'Degree - 2 digits, 0 decimals', 'Y-coordinate', 'Degree - 2 digits, 0 decimals', 'MDR', 'Ptosis', 'mm - 2 digits, 2 decimals', 'xml.', 'MDR2', 'mm - 2 digits, 2 decimals', 'xml.', 'Dynamic Acuity', 'Visual acuity', 'LogMAR 1 digit, 2 decimals', 'xml.', 'Dynamic Contrast', 'Contrast sensitivity', 'ConRatio 1 digit, 2 decimals', 'xml.', 'Fixed contrast', 'Hz 1 digit, 1 decimal', 'xml.', 'Dark Adaptation', 'Fixed frequency', 'ConRatio 1 digit, 2 decimals', 'xml.', 'Diameter (mm)', 'mm - 1 digit, 2 decimals', 'xml.', 'Peak velocity', 'mm/s - 1 digit, 2 decimals', 'xml.', 'Pupil', 'Latency', 'Ms 3 digits, 0 decimals', 'xml.', 'RAPDlog', '1 digit, 2 decimals', 'xml.', 'LogCon defined as -log10 (contrast ratio), EG if the low brightness part of the stimulus is 2', 'nits, the high brightness part 255 nits, the LogCon would be -log10 (2/255) =2, 1.', 'BulbiCam; Validity study:', 'V1_OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']\n\n###\n\n", "completion": "END"}